Loading...

Asia-Pacific Connected Health market intelligence service, 2016

Image

Subscriptions to our 2016 Asia-Pacific Connected Health market intelligence research program are now available. Receive accurate market data and reliable insight, access to specific business opportunities and the option to include private custom topics. Covering Devices, Systems and Services, the reports include analysis of: Connected Health ecosystem, government and hospital projects, regulations and reimbursement, industry players, case studies, future market outlook, and specific sales opportunities. 

Read More

new Indian mHealth device to tackle global health

Image

29-Mar-16 The Swasthya Slate device is a mobile platform that comprises of a hardware device that connects to a digital thermometer, a blood pressure monitor, heart rate sensor, a 3-lead ECG system, and a blood sugar monitor. The goal is to record and store data in the cloud very easily and quickly, says Kanov Kahol, who is credited with conceiving the device. [image: Swasthya]

Read More

All's not well with India's primary healthcare

Image

23-Mar-16 India's Primary Health Centres (PHCs) cater to the poorest of the population in remote areas, which can neither afford expensive treatment nor travel long distances to reach doctors in urban areas. With most of the MoUs with private agencies set for termination by this year-end, the government is racing against time to ensure the PHCs don't become non-functional. [image: Getty Images]

Read More

Practo launches operations in Brazil

Image

17-Mar-16 India’s largest doctor discovery platform Practo has launched services in Brazil, its sixth location. This makes it one of the few homegrown Indian consumer Internet startups to capitalize on high-growth global markets. Practo is already present in Singapore, the Philippines, Malaysia and Indonesia. [image: Practo]

Read More

India bans 350 combination drugs on safety grounds

Image

17-Mar-16 The Indian government has banned around 344 fixed dosed combination drugs, including Pfizer's cough syrup Corex, Procter & Gamble's Vicks Action 500 Extra and Crocin Cold and Flu, citing their potential risks. [image: Sajjad Hussain / AFP / Getty Images]

Read More
Share